<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260516</url>
  </required_header>
  <id_info>
    <org_study_id>FM-BSU REC</org_study_id>
    <nct_id>NCT04260516</nct_id>
  </id_info>
  <brief_title>The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major</brief_title>
  <official_title>The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of N-acetylcysteine as antioxidant and its effect on pretransfusion hemoglobin and
      iron overload in patients with thalassemia were compared to patients who didn't receive
      n-acetylcysteine after 3 months of study duration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      N-acetylcysteine( NAC) is a widely used mucolytic drug and several studies had reported its
      efficacy as anti oxidant. Patients with thalassemia major are at great risk for oxidative
      stress due to excess of b-globin chains and iron overload. In this study the investigators
      compared the effect of NAC on oxidative status , pretransfusion hemoglobin levels and iron
      overload in thalassemia patients before and after treatment with NAC for 3 months and with
      that of patients who served as controls.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 3, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups are followed up for study parameters for 3 months one group is the intervention group and the other is the control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidative stress index (pg/mmol)</measure>
    <time_frame>3 months</time_frame>
    <description>Oxidative stress index is calculated as the ratio of total oxidative status (pg/dl) to total anti oxidative capacity (mmol/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum ferritin level ( mg/dl)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Thalassemia Major</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received oral n-acetylcysteine syrup on dose of 10 mg/kg/day as single dose for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non n-acetylcysteine group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Thalassemia major patients on regular chelation therapy who didn't receive n-acetylcysteine and served as controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine</intervention_name>
    <description>Mucolytic and antioxidant drug</description>
    <arm_group_label>N-acetylcysteine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thalassemia major children on regular blood transfusion and iron chelation therapy

        Exclusion Criteria:

          -  Renal or hepatic impairments

          -  Complicated thalassemia major

          -  Non adherence to therapy or follow up visits

          -  Change in the iron chelation dose within 3 months before enrollment or during study
             period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heba M Ahmed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beni-Suef University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heba Mostafa Ahmed</name>
      <address>
        <city>Banī Suwayf</city>
        <state>Beni Suef</state>
        <zip>62115</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Ozdemir ZC, Koc A, Aycicek A, Kocyigit A. N-Acetylcysteine supplementation reduces oxidative stress and DNA damage in children with β-thalassemia. Hemoglobin. 2014;38(5):359-64. doi: 10.3109/03630269.2014.951890. Epub 2014 Sep 15.</citation>
    <PMID>25222041</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Heba Mostafa Ahmed</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

